Intranasal Scopolamine — INSCOP

Space motion sickness (SMS) commonly experienced by astronauts during a space mission often requires treatment with medication. However, exposure to a microgravity environment results in a myriad of physiological changes that alter bioavailability. In particular, studies indicate that the bioavailability of oral scopolamine (SCOP) is decreased during spaceflight. Although altered gastrointestinal function, including delayed gastric emptying, appears to contribute to decreased bioavailability of oral medications, other factors typical of spaceflight may influence the pharmacokinetics of medications administered via a variety of other non-parenteral routes.